IFNG Human, His Active
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 10 µg |
| Purification : | Greater than 90.0% as determined by SDS-PAGE. |
| Content : | IFNG protein solution (1mg/ml) containing Phosphate buffered saline (pH 7.4) and 20% glycerol. |
| Storage condition : | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles. |
| AA sequence : | MGSSHHHHHH SSGLVPRGSH MQDPYVKEAE NLKKYFNAGH SDVADNGTLF LGILKNWKEE SDRKIMQSQI VSFYFKLFKN FKDDQSIQKS VETIKEDMNV KFFNSNKKKR DDFEKLTNYS VTDLNVQRKA IHELIQVMAE LSPAAKTGKR KRSQMLFRG. |
| Alternative Name : | Immune Interferon, type II interferon, T cell interferon, MAF, IFNG, IFG, IFI, IFN-gamma. |
Source: Escherichia Coli.
Sterile Filtered colorless liquid.
IFN-gamma produced by lymphocytes activated by specific antigens or mitogens.IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions, it is a potent activator of macrophages, and has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
IFNG Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 159 amino acids (24-161 a.a) and having a molecular mass of 18.4kDa. IFNG is fused to a 21 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Measured in a cytotoxicity assay using WiDr cells. The ED50 for this effect is <= 5 ng/ml.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
Antonio J Ruiz-Malagón 1 2, Marina Herraiz-Vilela 1 2, Raquel Serrano-Pino 1 2, Paula García-Ávila 1 2, Luis Díaz-Suárez 1 3, Ada Dm Carmona-Segovia 1 4 5, Victor M Becerra-Munoz 1 4 5, Manuel Jiménez-Navarro 1 4 5 6, Isabel Arranz-Salas 1 7 8, Juan A López-Villodres 1 7 8, Alejandra Fernández-Castañer 1 2, Fernando Gutiérrez-Martínez 1 2, Francisco J Rodríguez-González 1 2, Raquel Camargo-Camero 1 2, Guillermo Alcaín-Martínez 1 2, Cristina Rodríguez-Díaz 1 2, Eduardo García-Fuentes 1 2 9, María J Sánchez-Quintero 1 4 5, Carlos López-Gómez
Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease
World J Gastroenterol
. 2025 Nov 7;31(41):110955. doi: 10.3748/wjg.v31.i41.110955.
PMID: 41257277 PMCID: PMC12620814 DOI: 10.3748/wjg.v31.i41.110955
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
